Tonghua Dongbao Pharmaceutical Co., Ltd.

Equities

600867

CNE000000H87

Pharmaceuticals

End-of-day quote Shanghai S.E. 23:00:00 11/07/2024 BST 5-day change 1st Jan Change
7.71 CNY +0.92% Intraday chart for Tonghua Dongbao Pharmaceutical Co., Ltd. -6.32% -28.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tonghua Dongbao Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 120 million worth of its shares. CI
Tonghua Dongbao Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Dongbao Pharmaceutical Gets EU GMP Certification MT
Dongbao Pharmaceutical Doses First Patient in Diabetes Drug Trial MT
Tonghua Dongbao Pharmaceutical Launches Phase 1 Trial for Diabetes Injection in China MT
Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake MT
JHM Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Tonghua Dongbao Pharmaceutical Co., Ltd. CI
JHM Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 100 million in funding from Tonghua Dongbao Pharmaceutical Co., Ltd. CI
Dongbao Pharmaceutical's Profit, Operating Income Slip in Q1 2024 MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Dongbao Pharma's 2023 Profit Drops 26% MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dongbao Pharma Unit's Gout Drug Clinical Study Achieves Primary Endpoint MT
Dongbao Pharmaceutical's Unit Gets Nod to Trial Diabetes Drug MT
Dongbao Pharmaceutical Unit Gets Nod to Trial Diabetes Drug MT
Tonghua Dongbao Pharma Unit Enrolls First Subject for Clinical Trial of Diabetes Drug MT
Tonghua Dongbao Pharma Registers Diabetes Drug MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tonghua Dongbao Pharmaceutical's Insulin Injection Shows Positive Results in German Trial MT
Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S CI
Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) added to S&P Global BMI Index CI
Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) added to FTSE All-World Index CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Tonghua Dongbao Pharmaceutical Co., Ltd.
More charts
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.71 CNY
Average target price
12.61 CNY
Spread / Average Target
+63.55%
Consensus
  1. Stock Market
  2. Equities
  3. 600867 Stock
  4. News Tonghua Dongbao Pharmaceutical Co., Ltd.
  5. Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake